Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Albertsons Companies Inc (ACI) vs Quest Diagnostics Inc (DGX) Price & Performance

Albertsons Companies IncTrade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

Albertsons Companies Inc vs Quest Diagnostics Inc — how do they compare? Albertsons Companies Inc trades at $12.14 (market cap $5.95B), while Quest Diagnostics Inc trades at $237.43 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 4.4× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays the higher dividend (5.55%). Which is the better fit depends on your goals.

ACIDGX
Market Cap
$5.95B$26.21B
Sector
Consumer StaplesHealth
52-Week High
$19.74$238.50
52-Week Low
$11.03$173.49
Enterprise Value
$21.35B$31.97B
Dividend Yield
5.55%1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Albertsons Companies Inc

Albertsons Companies (ACI) trades at $12.135, showing minimal daily movement with a 0.04% gain. The stock faces bearish technical signals despite recent insider buying by the CEO and CFO. Fundamentals reveal declining profitability with net income margin at just 0.08% and falling revenue growth, though valuation metrics like P/S of 0.08 appear attractive. Recent Q2 2026 earnings missed expectations, triggering a 22% selloff and multiple law firm investigations into potential securities violations.

ACI presents a high-risk opportunity with conflicting signals. While insider purchases and low valuation multiples suggest potential value, deteriorating margins, earnings misses, and legal scrutiny create significant headwinds. The stock's near-term trajectory depends on successful execution of the ACI Edge restructuring and digital initiatives to reverse profitability declines.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.

DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.

Returns comparison

Trailing returns across standard periods

About Albertsons Companies Inc

Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.

Read more on ACI

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX